LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Kodu・Aktsiate loetelu・United Therapeutics Corp

United Therapeutics Corp

Suletud

SektorTervishoid

567.25 -0.12

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

559.78

Max

569.82

Põhinäitajad
By Trading Economics
Sissetulek	-89M 275M
Müük	-8.7M 782M
P/E Sektori keskmine	20.882 51.415
Aktsiakasum	5.82
Kasumimarginaal	35.176
Töötajad	1,400
EBITDA	-176M 348M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+14.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-476M 24B
Eelmine avamishind	567.37
Eelmine sulgemishind	567.25

Uudiste sentiment

By Acuity

46%

54%

145 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

292.345 / 309.245 Toetus ja vastupanu

United Therapeutics Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. mai 2026, 23:10 UTC

Kuumad aktsiad

Stocks to Watch: Agilysys, XP

18. mai 2026, 18:44 UTC

Suurimad hinnamuutused turgudel

Claritev Shares Recover After Comments About DOJ

18. mai 2026, 23:55 UTC

Tulu

Review & Preview: Earnings' Last Gasp -- Barrons.com

18. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18. mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

18. mai 2026, 20:25 UTC

Tulu

Correct: XP 1Q Total Client Assets BRL1.53T

18. mai 2026, 20:23 UTC

Tulu

XP 1Q Total Client Assets BRL1.53B

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Adj EPS BRL2.49 >XP

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Rev BRL4.73B >XP

18. mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18. mai 2026, 19:00 UTC

Tulu

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18. mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18. mai 2026, 18:17 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18. mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18. mai 2026, 16:57 UTC

Omandamised, ülevõtmised, äriostud

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18. mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18. mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18. mai 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Vinci Doesn't Set Out Financial Details of Deal

18. mai 2026, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18. mai 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Vinci Buys Canada's Modern Group of Companies

Võrdlus sarnastega

Hinnamuutus

United Therapeutics Corp Prognoos

Hinnasiht

By TipRanks

14.16% tõus

12 kuu keskmine prognoos

Keskmine 649.08 USD 14.16%

Kõrge 738 USD

Madal 516 USD

Põhineb 13 Wall Streeti analüütiku instrumendi United Therapeutics Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi United Therapeutics Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

292.345 / 309.245Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

145 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.